Company: NIVFW
Filing Date: 2025-09-15
Form Type: F-1
Source: 0001213900-25-087717
Chunk: 101

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-15
Form: F-1
Chunk 101
---
 auditor, among other things, the audits of the financial statements, including whether any material information should be disclosed, in addition to issues regarding accounting and auditing principles and practices; |

| ● | reviewing and approving all proposed related party transactions, as defined in Item 404 of Regulation S-K under the Securities Act; |

| ● | reviewing and recommending the financial statements for inclusion within the Company’s quarterly earnings releases and to the Board for inclusion in its annual reports; |

| ● | discussing the annual audited financial statements with management and the independent registered public accounting firm; |

57

| ● | reviewing policies with respect to risk assessment and risk management; |

| ● | reviewing the adequacy and effectiveness of the Company’s accounting and internal control policies and procedures and any special steps taken to monitor and control major financial risk exposures; |

| ● | periodically reviewing and reassessing the adequacy of the committee charter; |

| ● | approving annual audit plans, and undertaking an annual performance evaluation of the internal audit function; |

| ● | establishing and overseeing procedures for the handling of complaints and whistleblowing; |

| ● | meeting separately and periodically with management, the internal auditors and the independent registered public accounting firm; |

| ● | monitoring compliance with the Company’s code of business conduct and ethics, including reviewing the adequacy and effectiveness of its procedures to ensure proper compliance; |

| ● | reporting periodically to the Board; and |

| ● | such other matters that are specifically delegated to the Company’s Audit Committee by the Board from time to time. |

A copy of the audit committee’s current charter is available at our corporate website at www.newgenivf.com. Compensation Committee. Our Compensation Committee (“Compensation Committee”) consists of Mr. Wing Fung Alfred Siu, Ms. Hei Yue Tina Fong, and Ms Florianna Ann Chi Wan Chan. The Chairman of the Compensation Committee is Mr. Siu. The Company has determined that Ms. Chan satisfies the “independence” requirements of Rule 5605(c)(2) of the Nasdaq Stock Market Listing Rules. The Compensation Committee assists the Board in reviewing and approving compensation structure, including all forms of compensation relating to the Company’s directors and executive officers. The Company’s Chief Executive Officer may not be present at any committee meeting during which their compensation is deliberated upon. The Compensation Committee is responsible for, among other things:

| ● | reviewing and evaluating the Company’s executive compensation and benefits policies generally; |

| ● | reviewing and recommending any incentive compensation or equity